Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases

Molecules

Volumn 14, Issue 3, 2009, Pages 1183-1226

  Robak, Tadeusz ^a   Korycka, Anna ^a   Ewa, Lech Maranda ^a   Robak, Pawel ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Cladribine; Clinical application; Clofarabine; Fludarabine; Forodesine; Mechanism of action; Nelarabine; Pentostatin; Purine nucleoside analogues

Indexed keywords

ANTINEOPLASTIC AGENT; PURINE NUCLEOSIDE;

HUMAN; LYMPHOPROLIFERATIVE DISEASE; REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; PURINE NUCLEOSIDES; TREATMENT OUTCOME;

EID: 63449116519     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules14031183     Document Type: Review

References (228)

1. Tallman, M.S.; Hakimian, D.; Variakojis, D.; Koslow, D.; Sisney, G.A.; Rademaker, A.W.; Rose, E.; Kaul, K. A single cycle of 2-chlorodeoxyadenosine results in complete remission in the majority of patients with hairy cell leukemia. Blood 1992, 80, 2203-2209.
2. Robak, T.; Korycka, A.; Kasznicki, M.; Wrzesien-Kus, A.; Smolewski, P. Purine nucleoside analogues for the treatment of hematological malignancies: Pharmacology and clinical applications. Curr. Cancer Drug Targets 2005, 5, 421-444.
3. Johnson, S.A. Nucleoside analogues in the treatment of hematological malignancies. Expert Opin. Pharmacother. 2001, 2, 929-943.
4. Robak, T.; Kasznicki, M. Alkylating agents and nucleoside analogues in the treatment of B-cell chronic lymphocytic leukemia. Leukemia 2002, 16, 1015-1027.
5. Robak, T.; Lech-Maranda, E.; Korycka, A.; Robak, E. Purine nucleoside analogs as immunosuppressive ans antineoplastic agents: mechanism of action and clinical activity. Curr. Med. Chem. 2006, 13, 3165-3189.
6. Pettit, A.R. Mechanism of action of purine analogues in chronic lymphocytic leukemia. Br. J. Haematol. 2003, 121, 692-702.
7. Robak, T. Current treatment options in hairy cell leukemia and hairy cell leukemia variant. Cancer Treat. Rev. 2006, 32, 365-376.
8. Pastor-Anglada, M.; Molina-Arcas, M.; Casado, F.J.; Bellosillo, B.; Colomer, D.; Gil, J. Nucleoside transporters in chronic lymphocytic leukemia. Leukemia 2004, 18, 385-393.
9. Robak, T. Recent progress in the management of chronic lymphocytic leukemia. Cancer Treat. Rev. 2007, 33, 710-728.
10. Kalinka-Warzocha, E.; Wajs, J.; Lech-Maranda, E.; Ceglarek, B.; Holowiecki, J.; Federowicz, I.; Walewski, J.; Czyz, J.; Robak, T.; Warzocha, K. Polish Lymphoma Research Group. Randomized comparison of cladribine alone or in combination with cyclophosphamide, and cyclophosphamide, vincristine and prednisone in previously untreated low-grade B-cell non-Hodgkin lymphoma patients: final report of the Polish Lymphoma Research Group. Cancer 2008, 113, 367-375.
11. Zinzani, P.L. Non-Hodgkin's lymphoma: the evolving role of purine analogues. Best Pract. Res. Clin. Haematol. 2002, 15, 505-516.
12. Hellmann, A.; Lewandowski, K.; Zaucha, J.M.; Bieniaszewska, M.; Halaburda, K.; Robak, T. Effect of a 2-hour infusion of 2-chlorodeoxyadenosine in the treatment of refractory or previously untreated Waldenström's macroglobulinemia. Eur. J. Haematol. 1999, 63, 35-41.
13. Johnson, S.A.; Oscier, D.G.; Leblond, V. Waldenstrom's macroglobulinaemia. Blood Rev. 2002, 16, 175-184.
14. Evens, A.M.; Gartenhaus, R.B. Treatment of T-cell non-Hodgkin's lymphoma. Curr. Treat Options Oncol. 2004, 5, 289-303.
15. Korycka, A.; Lech-Maranda, E.; Robak, T. Novel purine nucleoside analogues for hematological malignancies. Recent Patents AntiCancer Drug Discov. 2008, 3, 123-136.
16. rd; Waud, W.R. Purine nucleoside antimetabolites in development for the treatment of cancer. Curr. Opin. Investig. Drugs 2004, 5, 592-596.
17. Faderl, S.; Gandhi, V.; Keating, M.J.; Jeha, S.; Plunkett, W.; Kantarjian, H.M. The role of clofarabine in hematologic and solid malignancies--development of a next-generation nucleoside analog. Cancer 2005, 103, 1985-1995.
18. Pui, C.H.; Jeha, S.; Kirkpatrick, P. Clofarabine. Nat. Rev. Drug Discov. 2005, 4, 369-370.
19. Roecker, A.M.; Allison, J.C.; Kisor, D.F.; Nelarabine: efficacy in the treatment of clinical malignancies. Future Oncol. 2006, 2, 441-448.
20. Prus, K.L.; Averett, D.R.; Zimmerman, T.P. Transport and metabolism of 9-beta-Darabinofuranosylguanine in a human T-lymphoblastoid cell line nitrobenzylthioinosine-sensitive and - insensitive influx. Cancer Res. 1990, 50, 1817-1821.
21. Kisor, D.F. Nelarabine use in leukemias. Drugs Today 2006, 42, 455-465.
22. Balakrishnan, K.; Nimmanapalli, R.; Ravandi, F.; Keating, M.J.; Gandhi, V. Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells. Blood 2006, 108, 2392-2398.
23. Korycka, A.; Bloński, J.Z.; Robak, T. Forodesine (BCX-1777, Immucillin H)- a new purine nucleoside analogue: mechanism of action and potential clinical application. Mini Rev. Med. Chem. 2007, 7, 976-983.
24. Leung, G.; Tse, Ch-M. The role of mitochondrial and plasma mermbrane nucleoside transporters in drug toxicity. Expert Opin Drug Metab Toxicol. 2007, 3, 1-14.
25. de Wolf, C.; Jansen, R.; Yamaguchi, H.; de Haas, M.; van de Wetering, K.; Wijnholds, J.; Beijnen, J.; Borst, P. Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides. Mol Cancer Ther. 2008, 7, 3092-3102.
26. Takenaka, K.; Morgan, J.A.; Scheffer, G.L.; Adachi, M.; Stewart, C.F.; Sun, D.; Leggas, M.; Ejendal, K.F.; Hrycyna, C.A.; Schuetz, J.D. Substrate overlap between Mrp4 and Abcg2/Bcrp affects purine analogue drug cytotoxicity and tissue distribution. Cancer Res. 2007, 67, 6965-6972.
27. Krishnamurthy, P.; Schwab, M.; Takenaka, K.; Nachagari, D.; Morgan, J.; Leslie, M.; Du, W.; Boyd, K.; Cheok, M.; Nakauchi, H.; Marzolini, C.; Kim, R.B.; Poonkuzhali, B.; Schuetz, E.; Evans, W.; Relling, M.; Schuetz, J.D. Transporter-mediated protection against thiopurine-induced hematopoietic toxicity. Cancer Res. 2008, 68, 4983-4989.
28. Molina-Arcas, M.; Marce, S.; Villamor, N.; Huber-Ruano, I.; Casado, F.J.; Bellosillo, B.; Montserrat, E.; Gil, J.; Colomer, D. Equilibrative nucleoside transporter-2 (hENT2) protein expression correlates with ex vivo sensitivity to fludarabine in chronic lymphocytic leukemia (CLL) cells. Leukemia 2005, 19, 64-68.
29. Molina-Arcas, M.; Bellosillo, B.; Casado, F.J.; Montserrat, E.; Gil, J.; Colomer, D.; Pastor-Anglada, M. Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia. Blood 2003, 101, 2328-2334.
30. Mackey, J.R.; Galmarini, C.M.; Graham, K.A.; Joy, A.A.; Delmar, A.; Dabbagh, L.; Glubrecht, D.; Jewell, L.D.; Lai, R.; Lang, T.; Hanson, J.; Young, J.D.; Merle-Beral, H.; Binet, J.L.; Cass, C.E.; Dumontet, C. Quantitative analysis of nucleoside transporter and metabolism gene expression in chronic lymphocytic leukemia (CLL): identification of fludarabine-sensitive and -insensitive populations. Blood 2005, 105, 767-774.
31. Rodriquez, C.O.; Mitchell, B.S.; Ayres, M.; Eriksson, S.; Gandhi, V. Arabinosylguanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase. Cancer Res. 2002, 62, 3100-3105.
32. Van den Neste, E.; Cardoen, S.; Offner, F.; Bontemps, F. Old and new insights into the mechanisms of action of two nucleoside analogs active in lymphoid malignancies: fludarabine and cladribine (review). Intern. J. Oncol. 2005, 27, 1113-1124.
33. Adkins, J.C.; Peters, D.H.; Markham, A. Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies. Drugs 1997, 53, 1005-1037.
34. Malspeis, L.; Grever, M.R.; Staubus, A.E.; Young, D. Pharmacokinetics of 2-F-ara-A (9-beta-Darabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate. Semin. Oncol. 1990, 17, 18-32.
35. Hutton, J.J.; Von Hoff, D.D.; Kuhn, J.; Phillips, J.; Hersh, M.; Clark, G. Phase I clinical investigation of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate (NSC 312887), a new purine antimetabolite. Cancer Res. 1984, 44, 4183-4186.
36. Foran, J.M.; Oscier, D.; Orchard, J.; Johnson, S.A.; Tighe, M.; Cullen, M.H.; de Takats, P.G.; Kraus, C.; Klein, M.; Lister, TA. Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with "low-grade" non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia. J. Clin. Oncol. 1999, 17, 1574-1579.
37. Boogaerts, M.A. Oral fludarabine therapy in chronic lymphocytic leukemia--increased convenience. Hematology J. 2004, 5, 31-37.
38. Beutler, E. Cladribine (2-chlorodeoxyadenosine). Lancet 1992, 340, 952-956.
39. Carson, D.A.; Wasson, D.B.; Taetle, R.; Yu, A. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood 1983, 62, 737-743.
40. Seto, S.; Carrera, C.J.; Kubota, M.; Wasson, D.B.; Carson, D.A. Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J. Clin. Invest. 1985, 75, 377-383.
41. Griffig, J.; Koob, R.; Blakley, R.L.; Mechanism of inhibition of DNA synthesis by 2-chlorodeoxyadenosine in human lymphoblastic cells. Cancer Res. 1989, 49, 6923-6928.
42. Robertson, L.E.; Chubb, S.; Meyn, R.E.; Story, M.; Ford, R.; Hittelman, W.N.; Plunkett, W. Induction of apoptotic cell death in chronic lymphocytic leukemia 2-chloro-2'-deoxyadenosine and 9-β-D-arabinosyl-2-fluoroadenine. Blood 1993, 81, 143-150.
43. Carson, D.A.; Carrera, C.J.; Wasson, D.B.; Yamanaka, H. Proogrammed cell death and adenine deoxynucleotide metabolism in humans lymphocytes. Adv. Enzyme Regul. 1988, 27, 395-404.
44. Kawasaki, H.; Carrera, C.J.; Piro, L.D.; Saven, A.; Kipps, T.J.; Carson, D.A. Relationship of deoxycytydine kinase and cytoplasmic 5'nucloetidase to the chemothrapeutic efficacy of 2-chlorodeoxyadenosine. Blood 1993, 81, 597-601.
45. Marzo, I.; Perez-Gala, P.; Rubio-Felix, D.; Anel, A.; Naval, J. Cladribine induces apoptosis in human leukemia cells by caspase-dependent and -independent pathways acting on mitochondra. Biochemistry 2001, 359, 537-546.
46. Nomura, Y.; Inanami, O.; Takahashi, K.; Matsuda, A.; Kuwabara, M. 2-Chloro-2'-deoxyadenosine induces apoptosis through the Fas/Fas ligand pathway in human leukemia cell line MOLT-4. Leukemia 2000, 14, 299-306.
47. Johnston, J.B.; Daeninck, P.; Verburg, L.; Lee, K.; Williams, G.; Israels, L.G.; Mowat, M.R.; Begleiter, A. P53, mdm-2, bax and bcl-2 and drug resistance in chronic lymphocytic leukemia. Leuk. Lymphoma 1997, 26, 425-449.
48. Genini, D.; Budihardjo, I.; Plunkett, W.; Wang, X.; Carrera, C.J.; Cottam, H.B.; Carson, D.A.; Leoni, L.M. Nucleotide requirements for the in vitro activation of the apoptosis protein-activating factor-1-mediated caspase pathway. J. Biol. Chem. 2000, 275, 29-34.
49. Grutter, M.G. Caspases: key players in programmed cell death. Curr. Opinion Struct. Biol. 2000, 10, 649-655.
50. Bosanquet, A.G.; Sturm, I.; Wieder, T.; Essmann, F.; Bosanquet, M.I.; Head, D.J.; Dörken, B.; Daniel, P.T. Bax expression correlates with cellular drug sensitivity to doxorubicin, cyclophosphamide and chlorambucil but not fludarabine, cladribine or corticosteroids in B-cell chronic lymphocytic leukemia. Leukemia 2002, 16, 1035-1044.
51. Klopfer, A.; Hasenjager, A.; Belka, C.; Schulze-Osthoff, K.; Dorken, B.; Daniel, P. Adenine deoxynucleotides fludarabine and cladribine induces apoptosis in a CD95/Fas receptor, FADD and caspase-8- independent manner by activation of the mitochondrial cell death pathway. Oncogene 2004, 16, 9408-9418.
52. Johnson, S.A. Clinical pharmacokinetics of nucleoside analogues. Focus on haematological malignancies. Clin. Pharm. 2000, 39, 5-26.
53. Saven, A.; Cheung, W.K.; Smith, I.; Moyer, M.; Johannsen, T.; Rose, E.; Gollard, R.; Kosty, M.; Miller, W.E.; Piro, L.D. Pharmacokinetics study of oral and bolus intravenous 2-chlorodeoxyadenosine in patients with malignancy. J. Clin. Oncol. 1996, 14, 978-983.
54. Liliemark, J.; Albertioni, F.; Hassan, M.; Juliusson, G. One the bioavailability of oral and subcutaneous 2-chloro-2'-deoxyadenosine in humans: alternative routes of administration. J. Clin. Oncol. 1992, 10, 1514-1518.
55. Robak, T.; Blasinska-Morawiec, M.; Krykowski, E.; Hansz, J.; Komarnicki, M.; Kazimierczak, M.; Konopka, L.; Maj, S.; Hellmann, A.; Zaucha, J.M.; Urasinski, L.; Zdziarska, B.; Kotlarek-Haus, S.; Usnarska-Zubkiewicz, L.; Kuratowska, Z.; Dwilewicz-Trojaczek, J.; Holowiecki, J.; Krawczyk-Kulis, M.; Grieb, P. 2-chlorodeoxyadenosine (2-CdA) in 2-hour versus 24-hour intravenous infusion in the treatment of patients with hairy cell leukemia. Leuk. Lymphoma 1996, 22, 107-111.
56. Liliemark, J.; Juliusson, G. On the pharmacokinetics of 2-chloro-2'-deoxyadenosine in humans. Cancer Res. 1991, 51, 5570-5572.
57. Albertioni, F.; Pettersson, B.; Reichelová, V.; Juliusson, G.; Liliemark, J. Analysis of 2-chloro-2'-deoxyadenosine in human blood plasma and urine by high-performance liquid chromatography using solid-phase extraction. The Drug Monit 1994, 16, 413-418.
58. Liliemark, J.; Pettersson, B.; Juliusson, G. Determination of 2-chloro-2'-deoxyadenosine in human plasma. Biomed. Chromatogr. 1991, 5, 262-264.
59. Lindemalm, S.; Savic, R.M.; Karlsson, M.O.; Liliemark, J.; Juliusson, G.; Albertioni, F. Application of population pharmacokinetics to cladribine. BMC Pharmacol. 2005, 9,5:4.
60. Robak, T.; Korycka, A.; Robak, E. Older and new formulations of cladribine. Pharmacology and clinical efficacy in hematological malignancies. Recent Patents Anticancer Drug Discov. 2006, 1, 23-38.
61. Juliusson, G.; Heldal, D.; Hippe, E.; Hedenus, M.; Malm, C.; Wallman, K.; Stolt, C.M.; Evensen, S.A.; Albertioni, F.; Tjθnnfjord, G. Subcutaneous injections of 2-Chlorodeoxyadenosine for symptomatic hairy cell leukemia. J. Clin. Oncol. 1995, 13, 989-995.
62. Aldinucci, D.; Poletto, D.; Lorenzon, D.; Nanni, P.; Degan K.O.; Rapana,B.; Pinto, A.; Gattei, V. CD26 expression correlates with a reduced sensitivity to 2'-deoxycoformycin-induced growth inhibition and apoptosis in T-cell leukemia/lymphomas. Clin. Cancer Res. 2004, 10, 508-520.
63. Brogden, R.N.; Sorkin, E.M. Pentostatin: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in lymphoproliferative disorders. Drugs 1993, 4, 652-677.
64. Niitsu, N.; Yamaguchi, Y.; Umeda, M.; Honma, Y. Human monocytoid leukemia cells are highly sensitive to apoptosis induced by 2'-deoxycoformycin and 2'-deoxyadenosine: association with dATP-dependent activation of caspase-3. Blood 1998, 92, 3368-3375.
65. Venner, P.M.; Glazer, R.I.; Blatt, J.; Sallan, S.; Rivera, G.; Holcenberg, J.S.; Lipton, J.; Murphy, S.B.; Poplack, D.G. Levels of 2'-deoxycoformycin, adenosine, and deoxyadenosine in patients with acute lymphoblastic leukemia. Cancer Res. 1981, 41, 4508-4511.
66. Staubus, A.E.; Weinrib, A.B.; Malspeis, L. An enzymatic kinetic method for the determination of 2'-deoxycoformycin in biological fluids. Biochem. Pharmacol. 1984, 33, 1633-1637.
67. Smyth, J.F.; Paine, R.M.; Jackman, A.L.; Harrap, K.R.; Chassin, M.M.; Adamson, R.H.; Johns, D.G. The clinical pharmacology of the adenosine deaminase inhibitor 2'-deoxycoformycin. Cancer. Chemother. Pharmacol. 1980, 5, 93-101.
68. Major, P.P.; Agarwal, R.P.; Kufe, D.W. Clinical pharmacology of deoxycoformycin. Blood 1981, 58, 91-96.
69. Grever, M.R.; Siaw, M.F.; Jacob, W.F.; Neidhart, J.A.; Miser, J.S.; Coleman, M.S.; Hutton, J.J.; Balcerzak, S.P. The biochemical and clinical consequences of 2'-deoxycoformycin in refractory lymphoproliferative malignancy. Blood 1981, 57, 406-417.
70. Pui, C.H.; Jeha, S.; Kirkpatrick, P. Clofarabine. Nat. Rev. Drug Discov. 2005, 4, 369-370.
71. Lindemalm, S.; Liliemark, J.; Juliusson, G.; Larsson, R.; Albertioni, F. Cytotoxicity and pharmacokinetics of cladribine metabolite, 2-chloroadenine in patients with leukemia. Cancer Lett. 2004, 210, 171-177.
72. rd; Weitman, S. Discovery and development of clofarabine: a nucleoside analogue for treating cancer. Nat. Rev. Drug Discov. 2006, 5, 855-863.
73. Reichelova, V.; Liliemark, J.; Albertioni, F. Liquid chromatographic study of acid stability of 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine, 2-chloro-2'-deoxy-adenosine and related analogues. J. Pharm. Biomed. Anal. 1995, 13, 711-714.
74. King, K.M.; Damaraju, V.L.; Vickers, M.F.; Yao, S.Y.; Lang, T.; Tackaberry, T.E.; Mowles, D.A.; Ng, A.M.; Young, J.D.; Cass, C.E. A comparison of the transportability, and its role in cytotoxicity, of clofarabine, cladribine, and fludarabine by recombinant human nucleoside transporters produced in three model expression systems. Mol. Pharmacol. 2006, 69, 346-353.
75. Lotfi, K.; Månsson, E.; Spasokoukotskaja, T.; Pettersson, B.; Liliemark, J.; Peterson, C.; Eriksson, S.; Albertioni, F. Biochemical pharmacology and resistance to 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine, a novel analogue of cladribine in human leukemic cells. Clin. Cancer Res. 1999, 5, 2438-2444.
76. rd; Ealick, S.E. The structure of human deoxycytidine kinase in complex with clofarabine reveals key interactions for prodrug activation. Acta Crystallogr. D .Biol. Crystallogr. 2006, 62, 133-139.
77. rd; Montgomery, J.A.; Bennett, L.L.Jr. Comparison of the mechanism of cytotoxicity of 2-chloro-9-(2-deoxy-2-fluoro-beta-D- arabinofuranosyl)adenine, 2-chloro-9-(2-deoxy-2-fluoro-beta-Dribofuranosyl) adenine, and 2-chloro-9-(2-deoxy-2,2-difluoro-beta-D-ribofuranosyl)adenine in CEM cells. Mol. Pharmacol. 1999, 55, 515-520.
78. Gandhi, V.; Kantarjian, H.; Faderl, S.; Bonate, P.; Du, M.; Ayres, M.; Rios, M.B.; Keating, M.J.; Plunkett, W. Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias. Clin. Cancer Res. 2003, 9, 6335-6342.
79. Xie, K.C.; Plunkett, W. Deoxynucleotide pool depletion and sustained inhibition of ribunucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-9-(2-deoxy-2-fluoro-beta-D- arabinofuranosyl) adenine. Cancer Res. 1996, 56, 3030-3037.
80. Genini, D.; Adachi, S.; Chao, Q.; Rose, D.W.; Carrera, C.J.; Cottam, H.B.; Carson, D.A.; Leoni, L.M. Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood 2000, 96, 3537-3543.
81. Jeha, S.; Gandhi, V.; Chan, K.W.; McDonald, L.; Ramirez, I.; Madden, R.; Rytting, M.; Brandt, M.; Keating, M.; Plunkett, W.; Kantarjian, H. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood 2004, 103, 784-789.
82. Kantarjian, H.; Gandhi, V.; Cortes, J.; Verstovsek, S.; Du, M.; Garcia-Manero, G.; Giles, F.; Faderl, S.; O'Brien, S.; Jeha, S.; Davis, J.; Shaked, Z.; Craig, A.; Keating, M.; Plunkett, W.; Freireich, E.J. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 2003, 102, 2379-2386.
83. Kantarjian, H.M.; Gandhi, V.; Kozuch, P.; Faderl, S.; Giles, F.; Cortes, J.; O'Brien, S.; Ibrahim, N.; Khuri, F.; Du, M.; Rios, M.B.; Jeha, S.; McLaughlin, P.; Plunkett, W.; Keating, M. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J. Clin. Oncol. 2003, 21, 1167-1173.
84. Roecker, A.M.; Allison, J.C.; Kisor, D.F. Nelarabine: efficacy in the treatment of clinical malignancies. Future Oncol. 2006, 2, 441-448.
85. Prus, K.L.; Averett, D.R.; Zimmerman, T.P. Transport and metabolism of 9-beta-Darabinofuranosylguanine in a human T-lymphoblastoid cell line nitrobenzylthioinosine-sensitive and -insensitive influx. Cancer Res. 1990, 50, 1817-1821.
86. Rodriguez, C.O.J.; Mitchell, B.S.; Ayres, M.; Eriksson, S.; Gandhi, V. Arabinosylguanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase. Cancer Res. 2002, 62, 3100-3105.
87. Rodriguez, C.O.Jr.; Stellrecht, C.M.; Gandhi, V. Mechanisms for T-cell selective cytotoxicity of arabinosylguanine. Blood 2003, 102, 1842-1848.
88. Kline, J.P.; Larson, R. Clofarabine in the treatment of acute myeloid leukemia and acute lymphoblastic leukemia: a review. Expert Opin. Pharmacother. 2005, 6, 1-8.
89. Ghandi, V.; Plunkett, W. Clofarabine and nelarabine: two new purine nucleoside analogs. Curr. Opini. Oncol. 2006, 18, 584-590.
90. Beesley, A.H.; Palmer, M.L.; Ford ,J.; Weller, R.E.; Cummings, A.J.; Freitas, J.R.; Firth, M.J.; Perera, K.U.; de Klerk, N,H,.; Kees, U.R. In vitro cytotoxicity of nelarabine, clofarabine and flavopiridol in paediatric acute lymphoblastic leukaemia. Br. J. Haematol. 2007,137, 109-116.
91. Kisor, D.F.; Plunkett, W.; Kurtzberg, J.; Mitchell, B.; Hodge, J.P.; Ernst, T.; Keating, M.J.; Gandhi, V. Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies. J. Clin. Oncol. 2000, 18, 995-1003.
92. Gandhi, V.; Plunkett, W.; Rodriguez, C.O.Jr.; Nowak, B.J.; Du, M.; Ayres, M.; Kisor, D.F.; Mitchell, B.S.; Kurtzberg, J.; Keating, M.J. Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response. J. Clin. Oncol. 1998, 16, 3607-3615.
93. Evans, G.B.; Furneaux, R.H.; Lewandowicz, A.; Schramm, V.L.; Tyler, P.C. Synthesis of secondgeneration transition state analogues of human purine nucleoside phosphorylase. J. Med. Chem. 2003, 46, 5271-5276.
94. Clinch, K.; Evans, G.B.; Fleet, G.W.; Furneaux, R.H.; Johnson, S.W.; Lenz, D.H.; Mee, S.P.; Rands, P.R.; Schramm, V.L.; Taylor Ringia, E.A.; Tyler, P.C. Synthesis and bio-activities of Lenantiomers of two potent transition state analogue inhibitor of purine nucleoside phosphorylases. Org. Biomol. Chem. 2006, 4, 1131-1139.
95. Canduri, F.; Silva, R.G.; dos Santos, D.M.; Palma, M.S.; Basso, L.A.; Santos, D.S.; de Azevedo, W.F.Jr. Structure of human PNP complexed with ligands. Acta Crystallogr D. Biol. Crystallogr. 2005, 61, 856-862.
96. Bantia, S.; Miller, P.J.; Parker, C.D.; Ananth, S.L.; Horn, L.H.; Kilpatrick, J.M.; Morris, P.E.; Hutchison, T.L.; Montgomery, J.A.; Sandhu, J.S. Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)- a novel potent and orally active immunosuppressive agent. Intern. Immunopharmacol. 2001, 1,1199-1210.
97. Kicska, G.A.; Long, L.; Horig, H.; Fatrchild, C.; Tyler, P.C.; Furneaux, R.H.; Schramm, V.L.; Kaufman, H.L. Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes. PNAS 2001, 98, 4593-4598.
98. Banthia, S.; Kilpatrick, J.M. Purine nucleoside phosphorylase inhibitors in T-cell malignancies. Curr. Oppinion Drug Discov. Develop. 2004, 7, 243-247.
99. Ashcroft, M.; Kubbutat, M.H.; Vousden, K.H. Regulation of p53 function and stability by phosphorylation. Mol.Cell Biol. 1999, 19, 1751-1758.
100. Kilpatrick, J.M.; Morris, P.E.; Serota, D.G.jr.; Phillips, D.; Moore, D.R.; Bennett, J.C.; Babu, Y.S. Intravenous and oral pharmacokinetic study of BCX-1777, a novel purine nucleoside phosphorylase transition-state inhibitor. In vivo effects on blood 2'-deoxyguanosine in primates. Int. Immunopharmacol. 2003, 3, 541-548.
101. Piro, L.D.; Miller, W.E.; Carrera, C.J.; Carson, D.A.; Beutler, E. Hairy cell leukemia. N. Engl. J. Med. 1987, 317, 901-902 (letter).
102. Cheson, B.D.; Sorensen, J.M.; Vena, D.A. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C Protocol mechanism of the National Cancer Institute: a report of 979 patients. J. Clin. Oncol. 1998, 16, 3007-3015.
103. Juliusson, G.; Lenkei, R.; Liliemark, J. Flow cytometry of blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cell and lymphocyte subsets after treatment with 2-chlorodeoxyadenosie. Blood 1994, 83, 3672-3681.
104. von Rohr, A.; Schmitz, S.F.; Tichelli, A.; Hess, U.; Piguet, D.; Wernli, M.; Frickhofen, N.; Konwalinka, G.; Zulian, G.; Ghielmini, M.; Rufener, B.; Racine, C.; Fey, M.F.; Cerny, T.; Betticher, D.; Tobler, A. Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study. Ann. Oncol. 2002, 13, 1641-1649.
105. Tallman, M.S.; Zakarija, A. Hairy cell leukemia survival and relapse: Long-term follow-up of purine analogs-based therapy and approach for relapsed disease. Transfus Apheresis Sci. 2005, 32, 90-103.
106. Saven, A.; Burian, C.; Koziol, J.A.; Piro, L.D. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 1998, 92, 1918-1926.
107. Bastie, J.N.; Cazals-Hatem, D.; Daniel, M.T.; D'Agay, M.F.; Rabian, C.; Glaisner, S.; Noel-Walter, M.P.; Dabout, D.; Flandrin, G.; Dombret, H.; Poisson, D.; Degos, L.; Castaigne, S. Five years follow-up after 2-chlorodeoxyadenosine treatment in thirty patients with hairy cell leukemia: evaluation of minimal residual disease and CD4+ lymphocytopenia after treatment. Leuk. Lymphoma 1999, 35, 555-565.
108. Zinzani, P.L.; Tani, M.; Marchi, E.; Stefoni, V.; Alinari, L.; Musuraca, G.; Gabriele, A.; Pileri, S.; Baccarani, M. Long-term follow-up of front line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine. Haematol. 2004, 89, 309-313.
109. Goodman, G.R.; Burian, C.; Koziol, J.A.; Saven, A. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J. Clin. Oncol. 2003, 21, 891-896.
110. Hoffman, M.A.; Janson, D., Rose, E.; Rai, K.R. Treatment of hairy cell leukemia with cladribine: response , toxicity and long-term follow-up. J. Clin. Oncol. 1997, 15, 1138-1142.
111. Robak, T.; Blasinska-Morawiec, M.; Blonski, J.; Hellmann, A.; Halaburda, K.; Konopka, L.; Kotlarek-Haus, S.; Potoczek, S.; Hansz, J.; Dmoszynska, A.; Urasinski, I.; Zdziarska, B.; Dwilewicz-Trojaczek, J.; Holowiecki, J.; Skotnicki, A.B. 2-chlorodeoxyadenosine: (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant 7-year experience in Poland. Eur. J. Haematol. 1999, 62, 49-56.
112. Lauria, F.; Boachia, M.; Marotta, G.; Respadori, D.; Zinzani, P.L., Rondelli, D. Weekly administration of 2-chlorodeoxyadenosine in patients with hairy cell leukemia is effective and reduces infectious complications. Haematol. 1999, 84, 22-25.
113. Robak, T.; Jamroziak, K.; Gora-Tybor, J.; Blonski, J.Z.; Kasznicki, M.; Dwilewicz-Trojaczek, J.; Wiater, E.; Zdunczyk, A.; Dybowicz, J.; Dmoszynska, A.; Wojtaszko, M.; Zdziarska, B.; Calbecka, M.; Kostyra, A.; Hellmann, A.; Lewandowski, K.; Stella-Holowiecka, B.; Sulek, K.; Gawronski, K.; Skotnicki, A.B.; Nowak, W.; Zawilska, K.; Molendowicz-Portala, L.; Kloczko, J.; Sokolowski, J.; Warzocha, K.; Seferynska, I.; Ceglarek, B.; Konopka, L. Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective randomized, multicenter trial. Blood 2007,109, 3672-3675.
114. Liliemark, J.; Albertioni, F.; Hassan, M.; Juliusson, G. On the bioavailability of oral and subcutaneous 2-chloro-2-deoxyadenosine in humans: alternative routes of administration. J. Clin. Oncol. 1992, 10, 1514-1518.
115. Juliusson, G.; Heldal, D.; Hippe, E.; Hedenus, M.; Malm, C.; Wallman, K.; Stolt, C.M.; Evensen, S.A.; Albertioni, F.; Tjθnnfjord, G. et al. Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia. J. Clin. Oncol. 1995, 13, 989-995.
116. Spiers, A.S.; Parekh, S.J.; Bishop, M.B. Hairy cell leukemia: induction of complete remission with pentostatin (2'-deoxycoformycin). J. Clin. Oncol. 1984, 2,1336-1342.
117. Spiers, A.S.; Moore, D.; Cassileth, P.A.; Harrington, D.P.; Cummings, F.J.; Neiman, R.S.; Bennett, J.M;. O'Connell, M.J. Remissions in hairy cell leukemia with pentostatin (2'-deoxycoformycin). N. Engl. J. Med. 1987, 316, 825-830.
118. Kraut, E.H.; Bouroncle, B.A.; Grever, M.R. Pentostatin in the treatment of advanced hairy cell leukemia. J. Clin. Oncol. 1989, 7, 168-172.
119. Grever, M.R.; Doan, C.A.; Kraut, E.H. Pentostatin in the treatment of hairy cell leukemia. Best Pract. Res. Clin. Haematol. 2003, 16, 91-99.
120. Thaler, J.; Grünewald, K.; Gattringer, C.; Ho, A.D.; Weyrer, K.; Dietze, O.; Stauder, R.; Fluckinger, T.; Lang, A.; Huber, H. Long-term follow-up of patients with hairy cel leukaemia treated with pentostatin: lymphocyte subpopulations and residual bone marrow infiltration. Br. J. Haematol. 1993, 84, 75-82.
121. Dearden, C.R.; Matutes, E.; Hilditch, B.T.; Wansbury, G.J.; Catovsky, D. Long term follow-up patients with hairy cell leukemia after treatment with pentostatin or cladribine. Br. J. Haematol. 1999, 106, 515-519.
122. Ribeiro, P.; Bouaffia, F.; Peaud, P.Y.; Blanc, M.; Salles, B.; Salles, G.; Coiffier, B. Long-term outcome of patients with hairy cell leukemia treated with pentostatin. Cancer 1999, 85, 65-71.
123. Rafel, M.; Cervantes, F.; Beltrán, J.M.; Zuazu, F.; Hernández Nieto, L.; Rayón, C.; García Talavera, J.; Montserrat, E. Deoxycoformycin in the treatment of patients with hairy cell leukemia: results of a Spanish collaborative study of 80 patients. Cancer 2000, 88, 352-357.
124. Johnston, J.B.; Eisenhauer, E.; Wainman, N.; Corbett, W.E.; Zaentz, S.D.; Daeninck, P.J. Longterm outcome following treatment of hairy cell leukemia with pentostatin (Nipent): a National Cancer Institute of Canada study. Semin. Oncol. 2000, 27, 32-36.
125. Habermann, T.M.; Andersen, J.W.; Cassileth, P.A.; Bennett, J.M.; Oken, M.M. Sequential administration of recombinant interferon alpha and deoxycoformycin in the treatment of hairy cell leukaemia. Br. J. Haematol. 1992, 80, 466-471.
126. Flinn, I.W.; Kopecky, K.J.; Foucar, M.K.; Head, D.; Bennett, J.M.; Hutchison, R., Corbett, W.; Cassileth, P.; Habermann, T.; Golomb, H.; Rai, K.; Eisenhauer, E.; Appelbaum, F.; Cheson, B.; Grever, M.R. Long-term follow-up of remission duration, mortality and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood 2000, 96, 2981-2986.
127. Maloisel, F.; B enboubker, L.; Gardembas, M.; Coiffier, B.; Divine, M.; Sebban, C.; Blanc, M.; Abgrall, J.F.; Lederlin, P.; Harousseau, J.L.; Blaise, A.M.; Grosbois, B.; Morice, P.; Ghandour, C.; Castaigne, S. Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients. Leukemia 2003, 17, 45-51.
128. Grever, M.; Kopecky, K.; Foucar, M.K.; Head, D.; Bennett, J.M.; Hutchison, R.E.; Corbett, W.E.; Cassileth, P.A.; Habermann, T.; Golomb, H. et al. Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an Intergroup study. J. Clin. Oncol. 1995, 13, 974-982.
129. Else, M.; Ruchlemer, R.; Osuji, N.; Del Giudice, I.; Matutes, E.; Woodman, A.; Wotherspoon, A.; Swansbury, J.; Dearden, C.; Catovsky, D. Long remissions in hairy cell leukemia with purine analogs. A report of 219 patients with a median follow-up of 12.5 years. Cancer 2005, 104, 2442-2448.
130. Kantarjia n, H.; Schachner, J.; Keating, M.J. Fludarabine therapy in hairy cell leukemia. Cancer 1991, 67, 1291-1293.
131. Rai, K.R.; Peterson, B.L.; Appelbaum, F.R.; Kolitz, J.; Elias, L.; Shepherd, L.; Hines, J.; Threatte, G.A.; Larson, R.A.; Cheson, B.D.; Schiffer, C.A. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N. Engl. J. Med. 2000, 343, 1760-1767.
132. Robak, T.; Blonski, J.Z.; Kasznicki, M.; Blasińska-Morawiec, M.; Krykowski, E.; Dmoszyńska, A.; Mrugala-Spiewak, H.; Skotnicki, A.B.; Nowak, W.; Konopka, L.; Ceglarek, B.; Maj, S.; Dwilewicz-Trojaczek, J.; Hellmann, A.; Urasiński, I.; Zdziarska, B.; Kotlarek-Haus, S.; Potoczek, S.; Grieb, P. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood 2000, 96, 2723-2729.
133. Robak, T.; Bloński, J.Z.; Kasznicki, M.; Góra-Tybor, J.; Dmoszyńska, A.; Wojtaszko, M.; Skotnicki, A.B.; Nowak, W.; Hellmann, A.; Lewandowski, K.; Zdziarska, B.; Konopka, L.; Ceglarek, B.; Dwilewicz-Trojaczek, J.; Boguradzki, P.; Kuliczkowski, K.; Sulek, K.; Warzocha, K. Comparison of cladribine plus prednisone with chlorambucil plus prednisone in patients with chronic lymphocytic leukemia. Final report of the Polish Adult Leukemia. Final report of the Polish Adult Leukemia Group (PALG CLL1). Med. Sci. Monit. 2005, 11, 171-180.
134. Johnson, S.; Smith, A.G.; Löffler, H.; Osby, E.; Juliusson, G.; Emmerich, B.; Wyld, P.J.; Hiddemann, W.; The French Cooperative Group on CLL. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin and prednisone (CAP) for treatment of advanced stage chronic lymphocytic leukemia. Lancet 1996, 347, 1432-1438.
135. Leporrier, M.; Chevret, S.; Cazin, B.; Boudjerra, N.; Feugier, P.; Desablens, B.; Rapp, M.J.; Jaubert, J.; Autrand, C.; Divine, M.; Dreyfus, B.; Maloum, K.; Travade, P.; Dighiero, G. Binet, J.L.; Chastang, C.; The French Cooperative Group on Chronic Lymphocytic Leukemia. Randomized comparison of fludarabine, CAP, and CHOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 2001, 98, 2319-2325.
136. Keating, M.J. ; O'Brien, S.; Kantarjian, H.; Plunkett, W.; Estey, E.; Koller, C.; Beran, M.; Freireich, E.J. Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood 1993, 81, 2878-2884.
137. Steurer, M.; Pall, G.; Richards, S.; Bohlius, J.; Greil, R. Cochrane Haematologic Malignancies Group. Single agent purine analogues for the treatment of chronic lymphocytic leukemia: a systematic review and meta- analysis. Cancer Treat. Rev. 2006, 32, 377-389.
138. Robak, T.; Blonski, J.Z.; Kasznicki, M.; Konopka, L.; Ceglarek, B.; Dmoszyńska, A.; Soroka-Wojtaszko , M.; Skotnicki, A.B.; Nowak, W.; Dwilewicz-Trojaczek, J.; Tomaszewska, A.; Hellmann, A.; Lewandowski, K.; Kuliczkowski, K.; Potoczek, S.; Zdziarska, B.; Hansz, J.; Kroll, R.; Komarnicki, M.; Holowiecki, J.; Grieb, P. Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukemia- updated results of the multicentre study of 378 patients. Br. J. Haematol. 2000, 108, 357-368.
139. Keating, M.J.; O'Brien, S.; Lerner, S.; Koller, C.; Beran, M.; Robertson, L.E.; Freireich, E.J.; Estey, E.; Kantarjian, H. Long term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regiments as initial therapy. Blood 1998, 92, 1165-1171.
140. Pir o, L.D.; Carrera, C.J.; Beutler, E.; Carson, D.A. 2-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia. Blood 1988, 71, 1069-1073.
141. Dillman, R.O. Pentostatin (Nipent) in the treatment of chronic lymphocyte leukemia and hairy cell leukemia. Expert Rev. Anticancer Ther. 2004, 4, 27-36.
142. Boogaerts, M.A. Oral fludarabine therapy in chronic lymphocytic leukemia-increased convenience. Hematology 2004, 5, 31-37.
143. O'Brien, S.M.; Kantarjian, H.M.; Cortes, J.; Beran, M.; Koller, C.A.; Giles, F.J.; Lerner, S.; Keating, M. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J. Clin. Oncol. 2001, 19, 1414-1420.
144. Hallek, M.; Schmitt, B.; Wilhelm, M.; Busch, R.; Kröber, A.; Fostitsch, H.P.; Sezer, O.; Herold, M.; Knauf, W.; Wendtner, C.M.; Kuse, R.; Freund, M.; Franke, A.; Schriever, F.; Nerl, C.; Döhner, H.; Thiel, E.; Hiddemann, W.; Brittinger, G.; Emmerich, B.; German Chronic Lymphocytic Leukaemia Study Group. Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group. Br. J. Haematol. 2001,14, 342-348.
145. Eichhorst, B.F.; Busch, R.; Hopfinger, G.; Pasold ,R.; Hensel, M.; Steinbrecher, C.; Siehl, S.; Jöger, U.; Bergmann, M.; Stilgenbauer, S.; Schweighofer, C.; Wendtner, C.M,; Döhner, H.; Brittinger, G.; Emmerich, B.; Hallek, M.; German CLL Study Group. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006, 107, 885-891.
146. Flinn, I.W.; Neuberg, D.S.; Grever, M.R.; Dewald, G.W.; Bennett, J.M.; Paietta, E.M.; Hussein, M.A.; Appelbaum, F.R.; Larson, R.A.; Moore, D.F.Jr.; Tallman, M,S. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J. Clin. Oncol. 2007, 25, 793-798.
147. Catovsky, D.; Richards, S.; Matutes, E.; Oscier, D.; Dyer, M.J.; Bezares, R.F.; Pettitt, A.R,; Hamblin, T.; Milligan, D.W.; Child, J.A.; Hamilton, M.S.; Dearden, C,E.; Smith, A.G.; Bosanquet, A.G.; Davis, Z.; Brito-Babapulle, V.; Else, M.; Wade, R.; Hillmen, P; UK National Cancer Research Institute (NCRI) Haematological Oncology Clinical Studies Group; NCRI Chronic Lymphocytic Leukaemia Working Group. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukemia (the LRF CLL4 Trial): a randomized controlled trial. Lancet 2007, 370, 230-239.
148. Montillo, M.; Tedeschi, A.; O'Brien, S.; Di Raimondo, F.; Lerner, S.; Ferrajoli, A.; Morra, E.; Keating, M.J. Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia. Cancer 2003, 97, 114-120.
149. Robak, T.; Bloński, J.Z.; Kasznicki, M.; Góra-Tybor, J.; D wilewicz-Trojaczek, J.; Stella-Holowiecka, B.; Wolowiec, D. Cladribine combined with cyclophosphamide is highly effective in the treatment of chronic lymphocytic leukemia. Hematol. J. 2002, 3, 244-250.
150. Robak, T., Blonski, J.Z.; Jamroziak, K.; Gora-Tybor, J.; Stella-Holowiecka, B.; Konopka, L.; Ceglarek, B.; Warzocha, K.; Seferynska, I.; Kloczko, J.; Piszcz, J.; Calbecka, M.; Kostyra, A.; Dwilewicz-Trojaczek, J.; Wiater, E.; Dmoszynska, A.; Kowal, M.; Zawilska, K.; Grzywacz, A.; Hellmann, A.; Mital, A.; Zdunczyk, A.; Debowicz, J.; Kuliczkowski, K.; Potoczek, S.; Skotnicki, A.; Nowakowska-Domagala, M.; Lewandowski, K.; Sulek, K. Randomized comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamde in untreated patients with chronic lymphocytic leukemia: Report of the Polish Adult Leukemia Group (PALG-CLL3). Blood 2008, 112, 732a (Abstract 2103).
151. Weiss, M.A.; Maslak, P.G.; Jurcic, J.G.; Scheinberg, D.A.; Aliff, T.B.; Lamanna N.; Frankel S.R.; Kossman, S.E.; Horgan, D. Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia. J. Clin. Oncol. 2003, 21, 1278-1284.
152. Tsimberidou, A.M.; Keating, M.J.; Giles, F.J.; Wierda, W.G.; Ferrajoli, A.; Lerner, S.; Beran, M.; Andreeff, M.; Kantarjian, H.M.; O'Brien, S. Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia. Cancer 2004, 100, 2583-2591.
153. Bosch, F.; Ferrer, A.; López-Guillermo, A.; Giné, E.; Bellosillo, B.; Villamor, N.; Colomer, D.; Cobo, F.; Perales, M.; Esteve, J.; Altés, A.; Besalduch, J.; Ribera, J.M.; Montserrat, E. For the GELCAB (Grup per l'Estudi dels Limfomes a Catalunya i Balears). Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukemia. Br. J. Haematol. 2002, 119, 976-984.
154. Robak, T.; Góra-Tybo r, J.; Lech-Maranda, E.; Blonski, J.Z.; Kasznicki, M. Cladribine in combination with mitoxantrone and cyclophosphamide (CMC) in the treatment of heavily pretreated patients with advanced indolent lymphoid malignancies. Eur. J. Haematol. 2001, 66, 188-194.
155. Robak, T.; Bloński, J.Z.; Kasznicki, M.; Góra - Tybor, J.; Dwilewicz-Trojaczek, J.; Boguradzki, P.; Konopka, L.; Ceglarek, B.; Sulek, J.; Kuliczkowski, K.; Wolowiec D, Stella-Holowiecka B, Skotnicki AB, Nowak W, Moskwa-Sroka B, Dmoszynska, A.; Calbecka, M. Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia. Leukemia 2001, 15, 1510-1516.
156. Robak, T.; Blonski, J.Z.; Gora-Tybor, J.; Jamroziak, K.; Dwilewicz-Trojaczek, J.; Tomaszewska, A.; Konopka, L.; Ceglarek, B.; Dmoszynska, A.; Kowal, M.; Kloczko, J.;Stella-Holowiecka, B.; Sulek, K.; Calbecka, M.; Zawilska, K.; Kuliczkowski, K.; Skotnicki,A.B.; Warzocha, K.; Kasznicki, M. Polish Leukemia Group (PALG CLL2).Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2). Blood. 2006, 108, 473-479.
157. Robak, T. Novel monoclonal antibodies for chronic lymphocytic leukemia. Curr. Cancer Drug Targets 2008, 8, 156-171.
158. Keating, M.J.; O'Brien, S.; Albitar, M.; Lerner, S.; Plunkett, W.; Giles, F.; Andreeff, M.; Cortes, J.; Faderl, S.; Thomas, D.; Koller, C.; Wierda, W.; Detry, M.A.; Lynn, A.; Kantarjian, H. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide and rituximab as initial therapy for chronic lymphocytic leukemia. J. Clin. Oncol. 2005, 23, 4079-4088.
159. Wierda, W.; O'Brien, S.; Wen, S.; Faderl, S.; Garcia-Manero, G.; Thomas, D.; Do, K.A.; Cortes, J.; Koller, C.; Beran, M.; Ferrajoli, A.; Giles, F.; Lerner, S.; Albitar, M.; Kantarjian, H.; Keating, M. Chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab for relapsed and refractory chronic lymphocytic leukemia. J. Clin. Oncol. 2005, 23, 4070-4078.
160. Byrd, J.C.; Rai, K.; Peterson, B.L.; Appelbaum, F.R.; Morrison, V.A.; Kolitz, J.E.; Shepherd, L.; Hines, J.D.; Schiffer, C.A.; Larson, R.A. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective analysis of CALGB 9712 and CALGB 9011. Blood 2005,105, 49-53.
161. 1; Eichhorst, B.F.; Staib, P.; Boettcher, S.; Ritgen, M.; Stilgenbauer, S.; Mendila, M.; Kneba, M.; Döhner, H.; Fischer, K. Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL). Blood 2008, 112, 125a (Abstract 325).
162. Robak, T. ; Moiseev, S.; Dmoszynska, A.; Solal-Céligny, P.; Warzocha, K.; Javier Loscertales, J.; Catalano, J. MD.; Afanasiev, B.V.; Larratt, L.; Geisler, C.; Montillo, M.; Ganly, P.; Dartigeas, C.; Rosta, A.; Janssens, A.; Mendila, M.; Maurer, J.; Wenger, M.K. Rituximab, fudarabine, and cclophosphamide (R-FC) polongs pogression fee survival in relapsed or refractory chronic lymphocytic leukemia (CLL) cmpared with FC aone: Final results from the international randomized phase III REACH tial. Blood 2008, 112, LBA-1(Abstract 157420).
163. Robak, T.; Smolewski, P.; Cebula, B.; Grzybowska-Izydorczyk, O.; Bloński, J.Z. Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia. Eur. J. Haematol. 2007, 79, 107-113.
164. Robak, T.; Smolewski, P.; Cebula, B.; Szmigielska-Kaplon, A.; Chojnowski, K.; Blonski, J.Z.; Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma. Cancer 2006,107, 1542-1550.
165. Absi, A.; Hsi, E.; Kulaycio, M. Prolymphocytic leukemia. Curr. Treat Options Oncol. 2005, 6, 197-208.
166. Robak, T.; Robak, P. Current treatment options in prolymphocytic leukemia. Med. Sci. Monit. 2007, 13, RA 69-80.
167. Krishnan, B.; Matutes, E.; Dearden, C. Prolymphocytic leukemias. Semin Oncol. 2006, 33, 257-263.
168. Palomera, L.; Doming o, J.M.; Agullo, J.A.; Romero, M. Complete remission in T-cell prolymphocytic leukemia with 2-chlorodeoxyadenosine (Letter). J.Clin. Oncol. 1995, 13, 1284-1285.
169. Saven A, Lee T, Schlutz M, Jacobs A, Ellison D, Longmire R, Piro L. Major activity of cladribine in patients with de novo B-cell prolymphocytic leukemia. J. Clin. Oncol. 1997, 15, 37-43.
170. Mercieca, J.; Matutes, E.; Dearden, C.; MacLennan, K.; Catovsky, D. The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype. J. Clin. Oncol. 1994,12, 2588-2593.
171. Kantarjian, H.M.; Childs, C.; O'Brien, S.; Huh, Y.; Beran, M.; Schachner, J.; Koller, C.; Keating, M.J. Efficacy of fludarabine, a new adenine nucleoside analogue, in patients with prolymphocytic leukemia and the prolymphocytoid variant of chronic lymphocytic leukemia. Am. J. Med. 1991, 90, 223-228.
172. Dohner, H.; Ho, A.D.; Thaler, J.; Stryckmans, P.; Sonneveld, P.; de Witte, T.; Lechner, K.; Lauria, F, Bodewadt-Radzun, S.; Suciu, S. Pentostatin in prolymphocytic leukemia: phase II trial of the European Organization for Research and Treatment of Cancer Leukemia Cooperative Study Group. J. Natl. Cancer Inst. 1993, 85, 658-662.
173. Doorduijn, J.K.; Michiels, J.J. Effectiveness of fludarabine in end-stage prolymphocytic leukemia. Leukemia 1994, 8, 1439.
174. Jeha, S.; Razzouk, B.; Rytting, M.E.; Gaynon, P.S.; Kadota, R.; Rheingold, S.; Luchtman-Jones, L.; Shen, V.; Arceci, R.J.; Fernandez, M.; Weitman, S.; Steinherz, P.G. Phase II trials of clofarabine in relapsed or refractory pediatric leukemia.Blood 2004, 104,196a (Abstract 684).
175. Jeha, S.; Gaynon, P.S.; Steinherz, P.;Kadota, R.; Bomgaars, L.; Razzouk,B.; Luchtman-Jones, L.; Altman, A.; Rheingold, S.; Ritchey, A.K.; Shen, V.; Weiss, J.; Chan, K.W.; Craig, A.; Arceci, R.J. A Phase II, open-label study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood 2003, 102, 881a (Abstract 3277).
176. Jeha, S.; Steinherz, P.; Gaynon, P.S.;Rheingold, S.;Razzouk, B.; Ritchey, A.K.;Altman, A.; Albano, E.; Stine, K.; Chan, K.W.; Weiss, J.; Craig, A.;Arceci, R.J. A Phase II, open-label study of clofarabine in pediatric patients with refractory or relapsed acute myelogenous leukemia. Blood 2003, 102, 617a (Abstract 2278).
177. Jeha, S.; Gaynon, P.S.; Razzouk, B.I.; Franklin, J.; Kadota, R.; Shen, V.; Luchtman-Jones, L.; Rytting, M.; Bomgaars, L.R.; Rheingold, S.; Ritchey, K.; Albano, E.; Arceci, R.J.; Goldman, S.; Griffin, T.; Altman, A.; Gordon, B.; Steinherz, L.; Weitman, S.; Steinherz, P. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J. Clin. Oncol. 2006, 24, 1917-1923.
178. Gidwani, P.; Ramesh, K.H.; Liu, Y.; Kolb, E.A. The comparison of clofarabine and cytarabine in pediatric relapsed acute lymphoblastic leukemia: a case report. Chemotherapy 2008, 54, 120-124. 179. Karp, J.E.; Ricklis, R.M.; Balakrishnan, K.; Briel, J.; Greer, J.; Gore, S.D.; Smith, B.D.;
179. McDevitt, M.A.; Carraway, H.; Levis, M.J.; Gandhi, V. A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. Blood 2007, 110, 1762-1769.
180. Cohen, M.H.; Johnson, J.R.; Justice, R.; Pazdur, R.; FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma. Oncologist. 2008, 13, 709-714.
181. Kurtzberg, J.; Ernst, T.J.; Keating, M.J.; Gandhi, V.; Hodge, J.P.; Kisor, D.F.; Lager, J.J.; Stephens, C.; Levin, J.; Krenitsky, T.; Elion, G.; Mitchell, B.S. Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J. Clin. Oncol. 2005, 23, 3396-3403.
182. Berg, S.L.; Blaney, S.M.; Devidas, M.; Lampkin, T.A.; Murgo, A.; Bernstein, M.; Billett, A.; Kurtzberg, J.; Reaman, G.; Gaynon, P.; Whitlock, J.; Krailo, M.; Harris, M.B. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. J. Clin. Oncol. 2005, 23, 3376-3403.
183. Furman, R.R.; Iosava, G.; Isola, L.; Ravandi, F.; Zodelava, M.; Bennett, J.C.; Kilpatrick, J.M.; Bantia, S., Forodesine (FodosineTM), a PNP inhibitor active in relapsed or refractory T-cell leukemia patients (Phase II study). Blood 2005, 106, 259a (Abstract 881).
184. Stelljes, M.; Kienast, J.; Berning, B.; Gokbuget, M.; Hoelzer, D.; Silling, G.; Berdel, W.E.; Dahl, G.V.H.; Schissel, D.; Hemenway, M.; Gore, L.Forodesine in patients with refractory/relapsed TALL can induce prolonged stable remission with minimal toxicity before and after allogeneic hematopoietic stem cell transplantation. Blood 2006, 108, 427b (Abstract 5340).
185. Furman, R.R.; Gandhi, V.V.; Bennett, J.C.; Bantia, S.; Kilpatrick, J.M., Intravenous Forodesine (BCX-1777), a novel purine nucleoside phosphorylase (PNP) inhibitor, demonstrates clinical activity in phase I/II studies in patients with B-Cell acute lymphoblastic leukemia. Blood 2004, 104, 750a (Abstract 2743).
186. Ritchie, E.; Gore, L.; Roboz, G.J.; Feldman, E.; Ravandi, F.; Furman, R. Phase II study of forodesine, a PNP inhibitor, in patients with relapsed or refractory B-lineage acute lymphoblastic leukemia Blood 2006, 108, 533a (Abstract 1881).
187. Tondini, C.; Balzarotti, M.; Rampinelli, J.; Valagussa, P.; Luoni,M.; DePaoli, A.; Santoro, A.; Bonadonna, G. Fludarabine and cladribine in relapsed/refractory low-grade non-Hodgkin's lymphoma: a phase II randomized study. Ann. Oncol. 2000, 11, 231-233.
188. Robak, T.; Góra-Tybor, J.; Krykowski, E.; Walewski, J.A.; Borawska, A.; Pluzanska, A.; Potemski, P.; Hellmann, A.; Zaucha, J.M.; Konopka, L.; Ceglarek, B.; Durzynski, T.; Sikorska, A.; Michalak, K.; Urasinski, J.; Opalinska, J.; Dmoszynska, A.; Adamczyk-Cioch, M.B.; Kuratowska, Z'; Dwilewicz-Trojaczek, J.; Boguradzki, P.; Deren, M'; Maj, S.; Grieb, P. Activity of 2-chlorodeoxyadenosine (Cladribine) in 2-hour intravenous infusion in 94 previously treated patients with low grade non-Hodgkin's lymphoma. Leuk. Lymphoma. 1997, 26, 99-105.
189. Tulpule, A.; Schiller, G.; Harycy-Buchman, L.; Tulpule, A.; Schiller, G.; Harvey-Buchanan, L.A.; Lee, M.; Espina, B.M.; Khan, A.U.; Boswell, W.; Nathwani, B.; Levine, A.M. Cladribine in the treatment of advanced relapsed or refractory low and intermediate grade non-Hodgkin's lymphoma. Cancer 1998, 83, 2370-2376.
190. Blum, K.A.; Johnson, J.L.; Niedzwiecki, D.; Piro, L.D.; Saven, A.; Peterson, B.A.; Byrd, J.C.; Cheson, B.D. Cancer and Leukemia Group B Study 9153. Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153. Cancer 2006, 107, 2817-2825.
191. Kong, L.R.; Huang, C.F.; Hakimian, D.; Variakojis, D.; Klein, L.; Kuzel, T.M.; Gordon, L.I.; Zanzig, C.; Wollins, E.; Tallman, M.S. Long term follow-up and late complications of 2-chlorodeoxyadenosine in previously treated, advanced, indolent non-Hodgkin's lymphoma. Cancer 1998, 82, 957-964.
192. Saven, A.; Emanuele, S.; Kosty, M.; Koziol, J.; Ellison, D.; Piro, L. 2-Chlorodeoxyadenosine activity in patients with untreated, indolent non-Hodgkin's lymphoma. Blood. 1995, 86, 1710-1716.
193. Fridrik, M.A.; Jager, G.; Kienzer, H.R.; Hausmaninger, H.; Oppitz, P.; Krieger, O.; Zabernigg, A.; Lang, A.; Neubauer, M.; Weidinger, G.; Schiller, L.; Seewann, H.L.; Chott, A.; Linkesch, W. Efficacy and toxicity of 2-Chlorodeoxyadenosine (Cladribine)--2 h infusion for 5 days--as firstline treatment for advanced low grade non-Hodgkin's lymphoma. Eu.r J. Cancer 1998, 34, 1560-1564.
194. Liliemark, J.; Martinsson, U.; Cavallin-Ståhl, E.; Svedmyr, E.; Porwit, A.; Strömberg, M.; Juliusson, G. Cladribine for untreated or early low-grade non-Hodgkin's lymphoma. Leuk. Lymphoma 1998, 30, 573-581.
195. Robak, T.; Góra-Tybor, J.; Urbańska-Ryś, H.; Krykowski, E. Combination regimen of 2-chlorodeoxyadenosine (cladribine), mitoxantrone and dexamethasone (CMD) in the treatment of refractory and recurrent low grade non-Hodgkin's lymphoma. Leuk. Lymphoma. 1999, 32, 359-363.
196. Van den Neste, E.; Louviaux, I.; Michaux, J.L.; Sonet, A.; Bosly, A.; Doyen, C.; Mineur, P.; Andre, M.; Straetmans, N.; Coche, E.; Venet, C.; Duprez, T.; Ferrant, A. Phase I/II study of 2-chloro-2'-deoxyadenosine with cyclophosphamide in patients with pretreated B cell chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma. Leukemia 2000, 14, 1136-1142.
197. Armitage, J.O.; Tobinai, K.; Hoelzer, D.; Rummel, M.J. Treatment of indolent non-Hodgkin's lymphoma with cladribine as single-agent therapy and in combination with mitoxantrone. Int. J.Hematol. 2004, 79, 311-321.
198. Riccioni, R.; Caracciolo, F.; Galimberti, S.; Cecconi, N.; Petrini, M. Low dose 2-CdA schedule activity in splenic marginal zone lymphomas. Hematol. Oncol. 2003, 21, 163-168.
199. Zinzani, P.L.; Tani, M.; Fanti, S.; Stefoni, V.; Musuraca, G.; Vitolo, U.; Perrotti, A.; Fina, M.; Derenzini, E.; Baccarani, M. A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma. Cancer 2008, 112, 856-862.
200. Rummel, M.J.; Chow, K.U.; Karakas, T.; Jöger, E.; Mezger, J.; von Grünhagen, U.; Schalk, K.P.; Burkhard, O.; Hansmann, M.L.; Ritzel, H.; Bergmann, L.; Hoelzer, D.; Mitrou, P.S. Reduced dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. Eur. J. Cancer 2002, 38, 1739-1746.
201. Zinzani, P.L.; Magagnoli, M.; Bandandi, M.; Tani, M.; Stefoni, V.; Cellini, C.; Poggi, S.; Piccioli, M.; Pileri, S.; Tura, S. Long-term follow-up of hairy cell leukemia patients treated with 2-chlorodeoxyadenosine. Haematologica 2000, 85, 922-925.
202. Hagenbeek, A.; Eghbali, H.; Monfardini, S.; Resegotti, E.; Hoskin, J.; de Wolf Peeters, C.; Mc Lennan, K.; Staab-Renner, E.; Schott, A.; Teodorovic, I.; Negrouk, A.; van Glabbeke, M.; Marcus, R. Fludarabine compared with CVP chemotherapy in newly diagnosed patients with stages III and IV low grade malignant non-Hodgkin's lymphoma . Blood 2001, 98, 843a (Abstract 3501).
203. Cabanillas, F. Purine nucleoside analogs in indolent non-Hodgkin's lymphoma. Oncology 2000, 14, 13-15.
204. Klasa, R.J.; Meyer, R.M.; Shustik, C.; Sawka, C.A.; Smith, A.; Guevin, R.; Maksymiuk, A.; Rubinger, M.; Samosh, M.; Laplante, S.; Grenier, J.F. Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisone in patients with recurrent lowgrade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylatorcontaining regimen. J. Clin. Oncol. 2002, 20, 4649-4654.
205. Zinzani, P.L.; Stefoni, V.; Musuraca, G.; Tani, M.; Alinari, L.; Gabriele, A.; Marchi, E.; Pileri, S.; Bacarani, M. Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma. Cancer 2004, 100, 2190-2194.
206. Jöger, G.; Neumeister, P.; Brezinschek, R.; Hinterleitner, T.; Fiebiger, W.; Penz, M., Neumann, H,J.; Mlineritsch, B.; De Santis, M.; Quehenberger, F.; Chott, A.; Beham-Schmid, C.; Höfler, G.; Linkesch, W.; Raderer, M. Treatment of extranodal marginal zone B-cell lymphoma of mucosaassociated lymphoid tissue type with cladribine: a phase II study. J. Clin. Oncol. 2002, 20, 3872-3877.
207. Robak, T.; Lech-Maranda, E.; Janus, A.; Blonski, J.; Wierzbowska, A.; Gora-Tybor, J. Cladribine combined with cyclophosphamide and mitoxantrone is an active salvage therapy in advanced non-Hodgkin's lymphoma. Leuk Lymphoma. 2007, 48, 1092-1101.
208. Forstpointner, R.; Dreyling, M.; Repp, R.; Hermann, S.; Hönel, A.; Metzner, B.; Pott, C.; Hartmann, F.; Rothmann, F.; Rohrberg, R.; Böck, H.P.; Wandt, H.; Unterhalt, M.; Hiddemann, W.; German Low-Grade Lymphoma Study Group. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004, 104, 3064-3071.
209. Cohen, B.J.; Moskowitz, C.; Straus, D.; Noy, A.; Hedrick, E.; Zelenetz, A. Cyclophosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma. Leuk Lymphoma 2001, 42, 1015-1022.
210. Thomas, D.W.; Owen, R.G.; Johnson, S.A.N.; Hillmen, P.; Seymour, J,F.; Wolf, M.M.; Rule, S.A.J. Superior quality and duration of response among patients with mantle cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOP. Leuk. Lymphoma 2005, 46, 549-552.
211. Robak, T.; Smolewski, P.; Cebula, B.; Bloński, J.Z. Rituximab co mbined with cladribine or withcladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma. Cancer 2006, 107, 1542-1550.
212. Saven, A.; Burian, C.; Koziol, J.A.; Piro, L.D. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 1998, 92, 1918-1926.
213. Anaissie, E.J.; Kontoyianni s, D.P.; O'Brien, S.; Kantarjian, H.; Robertson, L.; Lerner, S.; Keating, M.J. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann.Intern. Med. 1998, 129, 559-566.
214. Van den Neste, E.; Delanno y, A.; Vandercam, B.; Bosly, A.; Ferrant, A.; Mineur, P.; Montfort,L.; Martiat, P.; Straetmans, N.; Filleul, B.; Michaux, J.L. Infectious complications after 2-chlorodeoxyadenosine therapy. Eur. J. Haematol. 1996, 56, 235-240. 215. Samonis, G.; Kontoyiannis, D.P. Infectious complications of purine analog therapy. Curr. Opin. Infect. Dis. 2001, 14, 409-413.
215. O'Brien, S. Infections complications of nucleoside analogs. In Hematology; the American Society of Hematology: USA, 1999; pp. 536-542.
216. Anaissie, E.J.; Kontoyiannis, D.P.; O'Brien, S.; Kantarjian, H.; Robertson, L.; Lerner, S.; Keating, M.J. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann. Intern. Med. 1998, 129, 559-566.
217. Perkins, J.G.; Flynn, J.M.; Howard, R.S.; Byrd, J.C. Frequency and type of serious infections in fludarabine -refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma : implications for clinical trials in this patients population. Cancer 2002, 94, 2033-2039.
218. Cheson, B.D. Infectious and immunosuppressive complications of purine analog therapy. J. Clin. Oncol. 1995, 13, 2431-2448.
219. O'Brien, S.; Kantarjian, H.; Beran, M.; Koller, C.; Talpaz, M.; Lerner, S.; Keating, M.J. Fludarabine and granulocyte colony stimulating factor (G-CSF) in patients with chronic lymphocytic leukemia. Leukemia 1997, 11, 1631-1635.
220. Sudhoff, T.; Arning, M.; Schneider, W. Prophylactic strategies to meet infectious complications in fludarabine treated CLL. Leukemia 1997, 11, S38-S41.
221. Byrd, J.C.; Hargis, J.B.; Kester, K.E.; Hospenthal, D.R.; Knutnson, S.W.; Diehl, L.F. Opportunistic pulmonary infections with fludarabine in previously treated patients with low-grade lymphoid malignancies: a role for Pneumocystic carini pneumonia prophylaxis. Am J, Hematol. 1995, 49, 135-142.
222. Samonis, G.; Kontoyiannis, D.P. Infections complications of purine analog therapy. Curr. Opinion Infect. Dis. 2001, 14, 409-413.
223. Mauro, F.R.; Foa, R.; Cerreti, R.; Giannarelli, D.; Coluzzi, S.; Mandelli, F.; Girreli, G. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. Blood 2000, 95, 2786-2792.
224. Kroft, S.H.; Tallman, M.S.; Shaw, J.M.; Thangavelu, M.; Peterson, L.C. Myelodysplasia following treatment of chronic lymphocytic leukemia (CLL) with 2-chlorodeoxyadenosine (2-CdA). Leukemia 1997, 11, 170.
225. Van Den Neste, E.; Louviaux, I.; Michaux, J.L.; Delanoy, A. Michaux, L.; Hagemeijer, A.; Scheiff, J.M.; Bosly, A.; Stractmans, N.; Ferrant, A. Myelodysplastic syndrome with monosomy 5 and/or 7 following therapy with 2-chloro-2'-deoxyadenosine. Br. J.Haematol. 1999, 105, 268-270.
226. Robak, T. Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukemia. Haematology 2004, 9, 387-400.
227. Cheson, B.D.; Vena, D.A.; Barrett, J.; Freidlin, B. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. J.Clin. Oncol. 1999, 17, 2454-2460.
228. Robak, T.; Bloński, J.Z.; Góra-Tybor, J.; Kasznicki, M.; Konopka, L.; Ceglarek, B.; Komarnicki, M.; Lewandowski, K.; Hellmann, A.; Lewandowski, K.; Moskwa, A.; Dmoszynska, A.; Sokolowska, B.; Dwilewicz-Trojaczek, A.; Tomaszewska, A.; Sulek, K.; Calbecka, M. Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukaemia treated with cladribine. Eur.J. Cancer 2004, 40, 383-389.